Thymosin Alpha 1 Applications in Immunotherapy

Thymosin Alpha 1 (Tα1) is an endogenous 28-amino-acid peptide originally isolated from thymic tissue. It functions as a broad-spectrum immunomodulator, enhancing both innate and adaptive immune responses through interaction with Toll-like receptors and downstream signalling pathways. In cancer settings, Tα1 has been used as an adjuvant to chemotherapy and immune checkpoint blockade, where it can synergise with cytotoxic drugs, mitigate treatment-related immunosuppression and improve tumour infiltration by effector lymphocytes. Beyond oncology, Tα1 has shown promise in antiviral therapy, bolstering T-cell, B-cell and natural killer cell activity in infections such as hepatitis B, hepatitis C and HIV. Efforts to overcome its short half-life have led to modified constructs with prolonged circulation and enhanced tissue penetration. This versatility underpins its continued exploration as a component of combination immunotherapy protocols across a range of malignancies and infectious diseases.

Research from Nature Portfolio

Recent foundational work has focused on engineering long-acting Tα1 variants to extend biological efficacy in vivo. A fusion protein combining Tα1 with the Fc domain of human IgG4 demonstrated a >25-hour half-life in murine models, a 13-fold increase over native peptide. This construct not only repaired chemotherapy-induced lymphocyte depletion but also enhanced antitumour efficacy in breast and melanoma xenografts. Improved outcomes were attributed to upregulated co-stimulatory molecule expression on dendritic cells, elevated secretion of IFN-γ and IL-2, and increased tumour infiltration by CD4+ and CD8+ T cells. These advances establish a robust platform for clinical development of Tα1-based biologics with optimised pharmacokinetics and immunostimulatory potential.

Thymosin Alpha 1 Applications in Immunotherapy publication trend

The graph below shows the total number of articles in thymosin alpha 1 applications in immunotherapy across all publications each year (not limited to Nature Index journals).

Technical terms

Thymosin Alpha 1 (Tα1): A 28-residue immunomodulatory peptide derived from prothymosin α, used to enhance immune responses in cancer and viral infections.

Fc fusion protein: A chimeric molecule combining a therapeutic peptide with the Fc region of an antibody to prolong serum half-life and improve effector function.

Toll-like receptors (TLRs): A family of pattern-recognition receptors that detect microbial components and activate innate immune signalling cascades.

Dendritic cells (DCs): Antigen-presenting leukocytes that initiate and regulate adaptive immune responses by stimulating T lymphocytes.

Synergistic effect: The enhanced therapeutic outcome achieved when two agents act together more effectively than the sum of their individual effects.

Xenograft model: An in vivo experimental system in which human tumour cells are implanted into immunocompromised animals to study cancer therapies.

References

1. Synergistic anti-cancer and attenuation effects of thymosin on chemotherapeutic drug vinorelbine in tumor-bearing zebrafish. Biomedicine & Pharmacotherapy (2023).
2. Mechanism and clinical application of thymosin in the treatment of lung cancer. Frontiers in Immunology (2023).
3. Thymosin α1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical Application. Molecules (2023).
4. Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life. Scientific Reports (2018).